利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.019 秒)

    Solid peroral contraceptive preparations
    2.
    发明申请
    Solid peroral contraceptive preparations 审中-公开
    固体口服避孕药

    公开(公告)号：US20070072836A1

    公开(公告)日：2007-03-29

    申请号：US11352898

    申请日：2006-02-13

    申请人： Sabine Fricke ,  Hagen Gericke ,  Ralf Ladwig ,  Alexander Buske ,  Harald Raethe

    发明人： Sabine Fricke ,  Hagen Gericke ,  Ralf Ladwig ,  Alexander Buske ,  Harald Raethe

    IPC分类号： A61K31/57

    CPC分类号： A61K31/57 ,  A61K31/567 ,  A61K2300/00

    摘要： The solid peroral contraceptive contains an effective ingredient combination of dienogest in a daily dosage of equal to or less than 2.0 mg and ethinyl estradiol in a daily dosage of less than 0.03 mg together with one or more pharmaceutically acceptable carriers. The dienogest is released in two stages, while the ethinyl estradiol is released with the first stage portion of the dienogest.

    摘要翻译： 固体口服避孕药含有日剂量等于或小于2.0mg的地那诺酯和乙炔雌二醇的有效成分组合，日剂量小于0.03mg，以及一种或多种药学上可接受的载体。 乙酰雌二醇分两个阶段释放，而乙炔雌二醇与去乙内酯的第一阶段部分一起释放。

    ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME
    5.
    发明申请
    ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME 审中-公开
    包含与药物辅助剂和/或异物组合的美容师和雌激素的口服抗生素，但不包含乳糖，以及制备它们的方法

    公开(公告)号：US20090117183A1

    公开(公告)日：2009-05-07

    申请号：US12258737

    申请日：2008-10-27

    申请人： Sabine Fricke ,  Manuela Pfeifer ,  Claus Claussen ,  Ralf Ladwig ,  Beate Buerglen

    发明人： Sabine Fricke ,  Manuela Pfeifer ,  Claus Claussen ,  Ralf Ladwig ,  Beate Buerglen

    IPC分类号： A61K9/24 ,  A61K31/566 ,  A61P15/18

    CPC分类号： A61K31/566 ,  A61K9/2054 ,  A61K9/2059

    摘要： The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17β-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo.

    摘要翻译： 该方法产生不含无乳糖的口服避孕药组合物，其含有孕激素和雌激素以及一种或多种药学上可接受的助剂和/或赋形剂的组合。 避孕组合物是含有孕激素和雌激素，诸如微晶纤维素和粘合剂如羟丙基纤维素但不含乳糖的填充材料的片剂，粉末或胶囊。 优选地，孕激素是依诺麦特，乙酸氯地孕酮或左炔诺孕酮，雌激素是炔雌醇，17β-雌二醇或戊酸雌二醇。 提供了一种改善口服避孕药妇女乳糖不耐症预防的方法。 标准28天循环或长期使用的口服避孕制剂含有低剂量但不含乳糖的孕激素和雌激素至少21个日剂量单位，并且最多含有不含活性成分的至多7个日剂量单位或 一个安慰剂

    Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
    6.
    发明授权
    Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same 失效
    含有睾酮/睾酮酯混合物的生物粘附片剂和用于产生具有相同的预定睾酮时间释放特性的方法

    公开(公告)号：US06977083B1

    公开(公告)日：2005-12-20

    申请号：US09806639

    申请日：1999-09-30

    申请人： Doris Huebler ,  Guenter Kaufmann ,  Michael Oettel ,  Holger Zimmermann ,  Michael Dittgen ,  Sabine Fricke ,  Manfred Boese ,  Ralf Ladwig ,  Sven Claussen ,  Carsten Timpe

    发明人： Doris Huebler ,  Guenter Kaufmann ,  Michael Oettel ,  Holger Zimmermann ,  Michael Dittgen ,  Sabine Fricke ,  Manfred Boese ,  Ralf Ladwig ,  Sven Claussen ,  Carsten Timpe

    IPC分类号： A61F13/00 ,  A61K9/00

    CPC分类号： A61K9/006

    摘要： The method of making a bioadhesive tablet for controlling testosterone blood level, especially in elderly men suffering from partial androgen deficiency, includes spray-drying an alcoholic solution or suspension of testosterone and at least one testosterone ester, preferably in a ratio of 1:10 to 1:1.5, separately or together, with an organic polymer and optionally one or more auxiliary ingredient to form an active ingredient premix. Then various other auxiliary ingredients are mixed, as needed, with the active ingredient premix to form the bioadhesive tablet with an active ingredient layer and an adhesive layer. The active ingredient layer contains an effective amount of the active ingredient premix. The adhesive layer includes auxiliary ingredients including the bioadhesive polymer. The bioadhesive tablet may be buccally administered to provide a predetermined timed release profile of testosterone, advantageously varying according to a circadian rhythm.

    摘要翻译： 制备用于控制睾酮血液水平的生物粘附片剂的方法，特别是在患有部分雄激素缺乏症的老年男性中，包括将睾酮和至少一种睾酮酯的醇溶液或悬浮液喷雾干燥，优选1:10至 1：1.5，分别或一起与有机聚合物和任选的一种或多种辅助成分形成活性成分预混物。 然后根据需要将各种其它辅助成分与活性成分预混合物混合以形成具有活性成分层和粘合剂层的生物粘附片剂。 活性成分层含有有效量的活性成分预混物。 粘合层包括辅助成分，包括生物粘附聚合物。 生物粘附片剂可以经口给药以提供睾酮的预定定时释放曲线，其有利地根据昼夜节律改变。

    BUCCAL APPLICATION SYSTEM COMPRISING 17A-ESTRADIOL
    7.
    发明申请
    BUCCAL APPLICATION SYSTEM COMPRISING 17A-ESTRADIOL 审中-公开
    包含17A-ESTRADIOL的BUCCAL应用系统

    公开(公告)号：US20120142656A1

    公开(公告)日：2012-06-07

    申请号：US13148300

    申请日：2010-02-02

    申请人： Thomas Gräser ,  Ralf Ladwig ,  Abdul-Abbas Al-Mudhaffar

    发明人： Thomas Gräser ,  Ralf Ladwig ,  Abdul-Abbas Al-Mudhaffar

    IPC分类号： A61K31/565 ,  C07J1/00 ,  A61P5/30

    CPC分类号： A61K9/006 ,  A61K31/565

    摘要： The invention relates to application systems for buccal application, comprising 17α-estradiol in a dosage of 50 to 400 μg, preferably 200 to 400 μg, particularly preferably 300 μg, together with one or more pharmaceutically acceptable additives or media for implementing the treatment or minimization of hot flashes in women having estrogen deficiencies.

    摘要翻译： 本发明涉及用于颊部应用的应用系统，其包含剂量为50至400μg，优选200至400μg，特别优选300μg的17α-雌二醇，以及用于实施治疗或最小化的一种或多种药学上可接受的添加剂或介质 女性患有雌激素缺乏症的潮热。